Citadel Advisors
ARKG icon

Citadel Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Citadel Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.9M Sell
562,500
-248,400
-31% -$7.27M ﹤0.01% 2698
2025
Q4 		$23.5M Buy
810,900
+116,700
+17% +$3.5M ﹤0.01% 2168
2025
Q3 		$19.3M Buy
694,200
+347,500
+100% +$8.78M ﹤0.01% 2389
2025
Q2 		$8.44M Sell
346,700
-319,500
-48% -$7M ﹤0.01% 3278
2025
Q1 		$13.8M Sell
666,200
-83,800
-11% -$2.11M ﹤0.01% 2461
2024
Q4 		$17.7M Buy
750,000
+135,100
+22% +$3.32M ﹤0.01% 2299
2024
Q3 		$15.7M Sell
614,900
-8,800
-1% -$224K ﹤0.01% 2320
2024
Q2 		$14.6M Buy
623,700
+362,300
+139% +$9.14M ﹤0.01% 2344
2024
Q1 		$7.52M Sell
261,400
-124,100
-32% -$3.73M ﹤0.01% 3339
2023
Q4 		$12.6M Buy
385,500
+111,900
+41% +$3.04M ﹤0.01% 2544
2023
Q3 		$7.62M Buy
273,600
+120,400
+79% +$3.94M ﹤0.01% 3031
2023
Q2 		$5.22M Buy
153,200
+3,100
+2% +$97.4K ﹤0.01% 3584
2023
Q1 		$4.51M Sell
150,100
-427,700
-74% -$13.3M ﹤0.01% 3984
2022
Q4 		$16.3M Sell
577,800
-2,200
-0.4% -$69.8K ﹤0.01% 2185
2022
Q3 		$19.1M Sell
580,000
-75,000
-11% -$2.75M ﹤0.01% 1922
2022
Q2 		$20.6M Sell
655,000
-20,300
-3% -$710K 0.01% 1825
2022
Q1 		$31M Buy
675,300
+97,100
+17% +$4.63M 0.01% 1512
2021
Q4 		$35.4M Sell
578,200
-197,200
-25% -$13.6M 0.01% 1464
2021
Q3 		$57.9M Sell
775,400
-143,800
-16% -$12.1M 0.01% 1014
2021
Q2 		$85M Sell
919,200
-107,000
-10% -$9.1M 0.02% 768
2021
Q1 		$91.1M Buy
1,026,200
+354,500
+53% +$35.2M 0.02% 631
2020
Q4 		$62.6M Buy
671,700
+647,200
+2,642% +$51.6M 0.02% 802
2020
Q3 		$1.56M Buy
+24,500
New +$1.44M ﹤0.01% 5192

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors's ARKG Position: Q1 2026 in Review

Citadel Advisors increased its ARK Genomic Revolution ETF (ARKG) stake by 714% in Q1 2026, buying an estimated $7.56M and bringing the position to 294,157 shares worth $7.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3623.

Citadel Advisors first reported a position in ARKG in Q2 2018 and has held it in 23 quarters since. The position peaked at $22.9M in Q3 2021. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Citadel Advisors held 294,157 shares of ARK Genomic Revolution ETF worth $7.77M as of Q1 2026.
  • Citadel Advisors bought 258,009 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $7.56M.
  • ARK Genomic Revolution ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3623 holding.
  • Citadel Advisors first reported a position in ARK Genomic Revolution ETF in Q2 2018 and has held it in 23 quarters since.
  • Citadel Advisors's ARK Genomic Revolution ETF position peaked at $22.9M in Q3 2021.
  • 218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.